|
Bob Fram has twenty-eight years experience in medical oncology, of which eight years have been in the biopharmaceutical industry. Most recently, he was Vice President, Clinical Development at ImmunoGen, leading their antibody-based clinical programs in oncology. Prior to ImmunoGen, Bob led oncology clinical development programs for small molecule anticancer drugs at Vertex Pharmaceuticals, Ilex Oncology, and Knoll Pharmaceuticals. He graduated from Harvard College (A.B., 1971) and Harvard Medical School (M.D., 1976). Dr. Fram completed his post-doctoral training in Internal Medicine at Columbia Presbyterian Medical Center and in Hematology and Oncology at Dana Farber Cancer Institute and Brigham and Women’s Hospital in Boston. Dr. Fram is board certified in Hematology, Oncology, and Internal Medicine and has served on the staff at Dana Farber Cancer Institute/Harvard Medical School and as an Associate Professor of Medicine at the University of Massachusetts Medical School and at the University of Maryland Cancer Center. He was a Clinical Associate Professor of Medicine at the Brown University Medical School. Dr. Fram has contributed to 80 publications in the fields of experimental therapeutics and Hematology/Oncology including journal articles, book chapters, and published abstracts. | 